Andrew Gengos Athira Pharma, Inc. (ATHA) insider trading activity

Andrew Gengos is CFO and Chief Business Officer of Athira Pharma, Inc.. Currently has a direct ownership of 97,532 shares of ATHA, which is worth approximately $56,568. The most recent transaction as insider was on Sep 05, 2024, when has been sold 1,272 shares (Common Stock) at a price of $0.57 per share, resulting in proceeds of $725. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 97.5K

0% 3M change

21.9% 12M change

Total Value Held $56,568

Andrew Gengos Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 05 2024	SELL Open market or private sale	$725 $0.57 p/Share	1,272 Reduced 1.29%	97,532 Common Stock
Sep 03 2024	BUY Grant, award, or other acquisition	-	5,000 Added 4.82%	98,804 Common Stock
May 20 2024	BUY Grant, award, or other acquisition	$13,400 $1.34 p/Share	10,000 Added 9.63%	93,804 Common Stock
Jun 07 2023	BUY Open market or private purchase	$51,000 $3.4 p/Share	15,000 Added 15.79%	80,012 Common Stock
Jun 05 2023	BUY Open market or private purchase	$135,450 $3.01 p/Share	45,000 Added 40.9%	65,012 Common Stock
Jun 02 2023	BUY Open market or private purchase	$57,034 $2.85 p/Share	20,012 Added 50.0%	20,012 Common Stock
Jan 05 2023	SELL Open market or private sale	$3,515 $2.91 p/Share	1,208 Reduced 1.42%	83,804 Common Stock
Jan 04 2023	BUY Grant, award, or other acquisition	-	5,000 Added 5.55%	85,012 Common Stock

Also insider at

CYT

Cyteir Therapeutics, Inc. Healthcare

Chief Business Officer

Andrew Gengos

CFO and Chief Business Officer

Lexington, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ATHA shares.

Notify only if

Value

Insider Trading

Get notified when an Athira Pharma, Inc. insider buys or sells ATHA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Athira Pharma, Inc.

Track Activities on ATHA

Account